{"id":504962,"date":"2020-09-01T12:16:01","date_gmt":"2020-09-01T12:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=504962"},"modified":"2020-09-01T12:16:01","modified_gmt":"2020-09-01T12:16:01","slug":"stargardt-disease-stgd-market-insights-epidemiology-and-market-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/stargardt-disease-stgd-market-insights-epidemiology-and-market-analysis-by-delveinsight_504962.html","title":{"rendered":"Stargardt Disease (STGD) Market Insights, Epidemiology, and Market Analysis By DelveInsight"},"content":{"rendered":"
\"Stargardt<\/a><\/div>\n

(Albany, US) DelveInsight has launched a new report on<\/strong> Stargardt Disease Market<\/strong><\/a><\/span><\/p>\n

 <\/p>\n

DelveInsight’s “Stargardt Disease<\/strong> (STGD) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Stargardt Disease (STGD) , historical and forecasted epidemiology as well as the Stargardt Disease (STGD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Stargardt Disease (STGD) market report provides current treatment practices, emerging drugs, Stargardt Disease (STGD) market share of the individual therapies, current and forecasted Stargardt Disease (STGD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Stargardt Disease (STGD) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

 <\/p>\n

Stargardt disease<\/strong> (STGD) is named after Karl Stargardt, a German ophthalmologist who first reported a case in his practice in 1901. It is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. It is a rare retinal disorder inherited in an autosomal recessive pattern. Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. It typically develops during childhood or adolescence, but the age of onset and rate of progression can vary.<\/p>\n

 <\/p>\n

View Free Sample Page:-  https:\/\/www.delveinsight.com\/sample-request\/stargardt-disease-stgd-market<\/a><\/span><\/strong><\/p>\n

 <\/p>\n

Stargardt Disease Treatment<\/strong><\/p>\n

The DelveInsight Stargardt Disease (STGD) market report gives a thorough understanding of the Stargardt Disease (STGD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. This segment of the report covers the detailed diagnostic methods or tests for Stargardt Disease (STGD). It covers the details of conventional and current medical therapies available in the Stargardt Disease (STGD) market for the treatment of the condition. It also provides Stargardt Disease (STGD) treatment algorithms and guidelines in the United States, Europe, and Japan.<\/p>\n

 <\/p>\n

Stargardt Disease Market<\/strong><\/p>\n

Stargardt disease has an autosomal recessive mode of inheritance associated with disease-causing mutations in the ABCA4 gene. It is both clinically and genetically highly heterogeneous. The presentation, clinical features, and progression of Stargardt disease vary widely from patient to patient. Fundus flavimaculatus is the term for the phenotypic presentation of Stargardt disease in which flecks are widely distributed throughout the fundus. It is important to note that the progression of vision loss does not correlate with the fundus appearance.<\/p>\n

 <\/p>\n

Stargardt Disease Report Scope<\/strong><\/p>\n